Three notes:
1. Results demonstrated that Linzess, developed by Ironwood Pharmaceuticals, was associated with a significant improvement in abdominal score compared to placebo in adult IBS-C patients.
2. The abdominal score includes symptoms that IBS-C patients identify as bothersome and important to treat, such as bloating, pain and discomfort.
3. Study results may “help physicians and patients have a more comprehensive discussion about these bothersome symptoms and ways to manage them,” Lin Chang, MD, vice chief of digestive diseases at the University of California Los Angeles, said in a June 16 news release.
Click here for more details on the clinical trial.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
